Liver-specific expression cassettes, vectors and uses thereof for expressing therapeutic proteins
US-2024398990-A1 · Dec 5, 2024 · US
Factor viii: remodeling and glycoconjugation of factor viii
US2016193353A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016193353-A1 |
| Application number | US-201615072044-A |
| Country | US |
| Kind code | A1 |
| Filing date | Mar 16, 2016 |
| Priority date | Oct 10, 2001 |
| Publication date | Jul 7, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
First claim
Opening claim text (preview).
What is claimed is: 1 . A covalent conjugate comprising Factor VIII and a linear or a branched poly(ethylene glycol), wherein the a linear or a branched poly(ethylene glycol) is conjugated directly onto the peptide backbone of Factor VIII or conjugated onto the peptide backbone of Factor VIII via a linker, wherein the in vivo half-life of the conjugate is increased by at least about 40% compared to the in vivo half-life of a wild-type Factor VIII, wherein the linear or branched poly(ethylene glycol) has a degree of polymerization of from about 1 to about 5,000. 2 . The covalent conjugate of claim 1 , wherein the linear or branched poly(ethylene glycol) has a degree of polymerization of from about 1 to about 1,000. 3 . The covalent conjugate of claim 2 , wherein the poly(ethylene glycol) is conjugated directly onto the peptide backbone of Factor VIII. 4 . The covalent conjugate of claim 2 , wherein the poly(ethylene glycol) is conjugated onto the peptide backbone of Factor VIII via a linker. 5 . The covalent conjugate of claim 3 , wherein the conjugate comprises at least two poly(ethylene glycol) moieties. 6 . The covalent conjugate of claim 4 , wherein the conjugate comprises at least two poly(ethylene glycol) moieties. 7 . The covalent conjugate of claim 1 , wherein the in vivo half-life of the conjugate is increased by at least about 60% compared to the in vivo half-life of a wild-type Factor VIII. 8 . The covalent conjugate of claim 1 , wherein the in vivo half-life of the conjugate is increased by at least about 80% compared to the in vivo half-life of a wild-type Factor VIII. 9 . The covalent conjugate of claim 1 , wherein the in vivo half-life of the conjugate is increased by at least about 100% compared to the in vivo half-life of a wild-type Factor VIII. 10 . The covalent conjugate of claim 5 , wherein the in vivo half-life of the conjugate is increased by at least about 60% compared to the in vivo half-life of a wild-type Factor VIII. 11 . The covalent conjugate of claim 5 , wherein the in vivo half-life of the conjugate is increased by at least about 80% compared to the in vivo half-life of a wild-type Factor VIII. 12 . The covalent conjugate of claim 5 , wherein the in vivo half-life of the conjugate is increased by at least about 100% compared to the in vivo half-life of a wild-type Factor VIII. 13 . The covalent conjugate of claim 6 , wherein the in vivo half-life of the conjugate is increased by at least about 60% compared to the in vivo half-life of a wild-type Factor VIII. 14 . The covalent conjugate of claim 6 , wherein the in vivo half-life of the conjugate is increased by at least about 80% compared to the in vivo half-life of a wild-type Factor VIII. 15 . The covalent conjugate of claim 6 , wherein the in vivo half-life of the conjugate is increased by at least about 100% compared to the in vivo half-life of a wild-type Factor VIII.
Assignees
Inventors
Classifications
the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Factors VIII · CPC title
Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates · CPC title
Erythropoietin [EPO] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016193353A1 cover?
- The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
- Who is the assignee on this patent?
- Novo Nordisk As
- What technology area does this patent fall under?
- Primary CPC classification C07K14/755. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Jul 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).